BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence
Back to Companies Directory

Eikon Therapeutics

Eikon Therapeutics logo

Website
https://www.eikontx.com/
Founded
2019

Eikon Therapeutics is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs. We are passionate about novel therapeutics and share the belief that a better understanding of fundamental human disease biology can lead to better medicines. We are driven to go beyond incremental improvements. Instead, our goal is to introduce new therapies into clinical practice that will improve and extend life. Our clinical programs in oncology leverage immune response modulation and synthetic lethality to improve cancer therapy, while our discovery efforts are focused on identifying novel targets through application of single-molecule imaging to the study of cancer and neurological diseases. By applying machine learning algorithms to the very large imaging data sets that emerge from our imaging platforms, we can advance our programs towards our ultimate goal of discovering and developing better medicines.

Eikon is seeking intellectually curious, passionate, and creative team members that are eager to apply their talents to empower interdisciplinary scientific exploration and ultimately create and develop novel medicines. To learn more about open positions, please visit: https://www.eikontx.com/join-us/#open-positions


Articles Mentioning This Company

Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Sept. 29, 2026     Business Intelligence
Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after one of its weakest years in recent memory.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.